Novartis Beats CAR-T Competitors To The Pricing Punch With Kymriah Approval

 
• By Mandy Jackson

Novartis got a leg up on its competition Aug. 30 with an earlier-than-expected approval for Kymriah in pediatric ALL, ending the CAR-T pricing mystery with its $475,000 price tag, which the company is positioning as a relative bargain.

Destruction of leukaemia cell, conceptual image. 3D illustration which can be used to illustrate blood cancer treatment

More from New Products

More from Scrip